LED is a relatively benign, autoimmune condition that affects the dog's nasal planum and in which systemic manifestations are absent.
It is the second most common immune-mediated skin pathology in dogs.
Exposure to ultraviolet light aggravates and exacerbates LED and there are breeds that may be predisposed since they are reported more frequently, as the Collie, Shetland Sheep Dog, Australian Shepherd, German Shepherd and Siberian Husky.
Therapeutic approaches are multiple and different effectiveness has been reported.
In recent years, new therapeutic options have been developed for the management of CAD, and, in parallel with the evolution in the knowledge of the pathophysiology of this condition, a new way of looking at the manner we use these new therapies has also emerged.
Currently, a proactive therapeutic approach is emphasized in which, while correcting the underlying pathogenesis whenever possible, active relapses are actively prevented, through a constant control of the inflammation associated with the allergic condition.
In this new therapeutic approach, the management of CAD is done in two phases:
A first phase of REACTIVE therapy, in which the active clinical signs (pruritic and lesional being acute or chronic) is rapidly controlled in order to induce clinical remission;
A second phase of PROACTIVE therapy with the goal of preventing relapses, through the regular control of subclinical inflammation.